DENTSPLY SIRONA Inc. (XRAY) — Fair Value Analysis

Base-case fair value (P50): $19.00 · Current price: $12.12 · Verdict: Undervalued

The Verdict on XRAY

DENTSPLY SIRONA INC (XRAY) appears to be significantly undervalued, according to our Monte Carlo simulations. With a current price of $12.12, XRAY trades well below its median fair value (P50) of $19.00. This gap suggests a substantial upside potential of +56.8%, leading to a "Deeply Undervalued" verdict from our analysis. Our simulations indicate that the market may not be fully appreciating XRAY's intrinsic value, presenting a compelling opportunity for investors seeking exposure to the medical devices sector.

How XRAY stacks up against peers

Despite its "Deeply Undervalued" status, XRAY's operational and financial health is categorized as "average" when compared to its sector peers. This quality tier suggests that while the company's fundamentals are sound, there isn't a distinguishing advantage over competitors in terms of overall health. The significant +56.8% derived from the $19.00 fair value relative to the $12.12 is thus not predicated on exceptional operational outperformance but rather a disconnect between market price and projected long-term cash flows. Investors should weigh this "average" quality against the attractive valuation signal.

What this means for investors

For investors, the current valuation of DENTSPLY SIRONA INC presents a scenario where the market price of $12.12 is substantially below the estimated $19.00 fair value. The +56.8% indicates a strong potential for capital appreciation, even with an "average" quality tier. Our Monte Carlo simulations, which consider thousands of forward scenarios, repeatedly point to a significantly higher intrinsic value for XRAY. This implies that the stock has considerable room to re-rate closer to its fundamental value. Sign up for a free FairCurve account to see the full bear/bull distribution and track XRAY's fair value as new fundamentals are released.